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Abstract 
Bisphosphonates (BP) are a type of drug known to inhibit bone resorption through complex interventions. Their 
primary mechanism of action is aimed at the cellular level, inhibiting osteoclast activity and so bone resorption. 
BPs are widely used, with many patients receiving continuous treatment for years. But it is well known that these 
drugs can produce osteonecrosis of the jaw (ONJ). Zoledronic acid (ZA) is an intravenous BP used in the treatment 
and prophylaxis of bone disease in patients with malignant tumors with bone implication. ZA is the most potent BP 
in clinical development.
This report describes the case of a 62-year-old woman with breast cancer antecedents which relapsed, who had 
received a maxillary dental implant two years before the start of therapy with zoledronic acid. She later developed 
osteonecrosis of the jaw (ONJ), which began in the peri-implant area, and was treated for stage 3 ONJ by sub-total 
maxillectomy.
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Introduction
Bisphosphonates (BP) are a type of drug known to inhi-
bit bone resorption through complex mechanisms. Their 
primary action is aimed at the cellular level, inhibiting 
osteoclast activity and so bone resorption, particularly 
when administered by intravenous infusion. Because 
some breast cancer treatments can cause bone loss (os-
teoporosis), many women in treatment for breast cancer 
are also prescribed a BP (1).
Osteonecrosis of the jaw (ONJ) is an oral complication 
of bisphosphonate medication. Bisphosphonate-related 
ONJ will include a previous history of bisphosphona-
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te receipt, bone exposure, and absence of radiotherapy 
to the maxilla. The strength of the bisphosphonate, du-
ration of exposure, and an antecedent of bone trauma, 
condition ONJ development. Zoledronic acid (ZA) is a 
bisphosphonate used in the treatment and prophylaxis 
of bone disease in patients with malignant tumors with 
bone implication. ZA is the most potent BP in clinical 
development. The potential anticancer activity of zole-
dronic acid (ZA) may be mediated through its effects 
on the bone marrow microenvironment. In addition, pre-
clinical evidence suggests that ZA treatment interferes 
directly or indirectly with other processes in cancer pro-
gression and tumor growth (2). 
This article describes the case of a female patient with 
zoledronic acid-related ONJ with extensive maxillary 
affectation in the area where an implant had been placed 
2 years before starting treatment with zoledronic acid. 
The case was resolved by left-side subtotal maxillec-
tomy that included part of the nasal fossa floor and nasal 
mucosa and the anterior maxillary sinus wall and floor.    
Case Report
A 62-year-old woman came to the Oral and Maxillofa-
cial Surgery clinic at Virgen de las Nieves University 
Hospital (Granada, Spain) with an intraoral lesion of se-
veral months’ evolution. As a medical antecedent, it was 
noted that the patient had been diagnosed with breast 
cancer in 1993 and treated with surgery, chemotherapy, 
and radiotherapy. In 2005 she suffered a relapse of the 
cancer which was again treated with surgery, chemothe-
rapy, and radiotherapy. At the end of 2010 she was diag-
nosed with bone metastasis in the right supra-acetabular 
iliac blade, and was prescribed adjuvant drug treatment 
with intravenous ZA (1 dose per month for 14 months). 
The patient had received dental implant treatment 2 
years before starting treatment with ZA, which consisted 
of one implant at 24 (which was missing; all teeth were 
present in the rest of the dental arch) and implants to 
replace teeth 14 and 16. Before the oral lesion appeared, 
the patient was being treated for peri-implantitis in the 
region of the implant at 24. She had suffered discomfort 
since the beginning of 2011 in the left maxillary pre-
molar region. In September 2011, extraction of 25 was 
performed, which presented percussion pain and asso-
ciated pathology, while the implant at 24 was maintai-
ned. Antibiotic treatment with oral doxycycline, 500 mg 
once a day for 1 month, was prescribed in December 
2011 as the onset of ONJ was suspected.  As symptoms 
persisted, the patient attended regular check-ups but no 
infection focus or evident bone necrosis were observed 
and the patient continued peri-implantitis treatment. In 
October 2013, the patient presented implant mobility at 
24 with associated infection and areas of bone necrosis. 
Clinical exploration identified an extensive ulcer in the 
left maxilla with bone exposure (necrotic bone exposure 
of the alveolar bone at the implant site at 24), but compu-
terized tomography (CT) revealed that necrosis extended 
from 21 to 25 (although bone exposure had only occurred 
in the area of 24). The suspected diagnosis was of a lesion 
compatible with bisphosphonate-related osteonecrosis. 
Associated with this lesion, the patient also presented an 
intraoral fistula with purulent drainage. An orthopantomo-
graph and facial CT were made (Fig.1), which confirmed 
the diagnosis of stage 3 bisphosphonate-related ONJ (3).
In February 2014, after several days in hospital, when 
mouth washing with a 0.12% chlorhexidine glucona-
te solution was prescribed every 8 hours (Perio Aid, 
Dentaid, Barcelona, Spain) and intravenous antibiotic 
treatment with amoxicillin+calvulanic acid (Augmentin 
IV powder solution injected 1 g/200mg every 8 hours) 
for managing the superinfection, it was decided to per-
form radical surgery of the ONJ area. Under general 
anesthetic subtotal maxillectomy was performed from 
21 to 26 including the entire osteonecrosis area, the floor 
of the nasal fossa and mucosa, and anterior floor and 
wall of the maxillary sinus (Fig. 2). Bone defect cove-
rage was performed with direct closure by gingiva and 
vestibular mucosa. Pathological anatomy of the surgica-
lly-removed piece confirmed ONJ diagnosis. Antibiotic 
Fig. 1. CT shows left side maxillary osteonecrosis.
Fig. 2. Surgical procedure of maxillary necrosis resection.
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treatment continued for a further 10 days after surgery, 
together with 0.12% chlorhexidine mouth washing for 
a further 2 months. The patient returned for a check-up 
every 2 weeks to monitor the case’s evolution. Ten mon-
ths after surgery, the patient was seen to be in clinical 
and radiographic remission. 
Discussion
Patients with breast cancer are often treated intravenously 
with ZA or other BPs to suppress osteoclast activity as in 
the classic case described here (2). As many studies have 
suggested, patients who receive intravenous BP therapy 
along with additional chemotherapy and corticosteroids 
are at a high risk of ONJ (4,5).
In this way, for patients in treatment with bisphospho-
nates, the current objective of case management is ONJ 
prevention (6). It is essential to find out if a patient is 
or has been in treatment with bisphosphonates; this re-
quires exhaustive exploration of medical histories, given 
that patients will not always remember what medication 
they were prescribed years earlier. The health professio-
nal must know what bisphosphonate the patient is taking 
or has taken, the route of administration (as this condi-
tions the risk of developing ONJ as intravenous bisphos-
phonates lead to a higher risk of ONJ), for how long, the 
indication, and frequency. 
In recent years, the number of cases of ONJ following 
dental implant insertion in patients treated with bisphos-
phonates has been increasing (7). Importantly, ONJ may 
appear in a peri-implant area, particularly when implants 
have been placed some time before starting bisphospho-
nate therapy as in the present case (implants placed 2 
years before BP administration). For this reason, it 
would appear advisable that patients who are or have 
been in treatment by bisphosphonates and also have den-
tal implants should undergo a check-up every 6 months, 
as peri-implantitis can be a warning signal for the on-
set of ONJ. Furthermore, the patient should be warned 
when considering dental implant therapies that if he/she 
is taking or is going to take bisphosphonates, then re-
gular check-ups are advisable. The patient should give 
informed consent in writing to the effect that he/she un-
derstands that implant failure is a possibility as well as 
ONJ in the peri-implant area.  
The main approach to treating ONJ are the manage-
ment of symptoms, infection, and to prevent new areas 
of ONJ from developing, and are conditioned by ONJ 
stage (3). Stage 1 requires conservative treatment; stage 
2 local and systemic antibiotic treatment, chlorhexidine 
mouthwashes, and local debridement where necessary; 
stage 3, which presents extensive areas of necrosis and 
infection, will need radical surgery rather than local de-
bridement (as in the present case) but in no case is re-
construction with autologous bone or vascularized bone 
grafting indicated.  
Physicians must be informed and trained to deal with 
this new clinical entity, in order to establish prophylactic 
care, early diagnosis, and to prevent the potentially de-
vastating consequences (8). Moreover, close coordina-
tion between the general practitioner prescribing BP and 
the dentist is essential for reducing the risk of BP-related 
ONJ in patients starting BP therapy (9).
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